Israeli drug company SciVac is seeking U.S. approval for a widely used
hepatitis B vaccine as part of a push for increased global sales of a
product which it says could stem global growth in the disease.
SciVac's Sci-B-Vac, already given to the
majority of Israeli children just after birth, comprises all three
native proteins of the virus, compared with just one protein in an older
vaccine from GlaxoSmithKline's called Engerix-B and cheaper copycats
Dosage of Sci-B-Vac is just a quarter that of Engerix.
Labels: clinical trials, drugs in development, Research and Discoveries, vaccine